PUBLISHER: IMARC | PRODUCT CODE: 1541386
PUBLISHER: IMARC | PRODUCT CODE: 1541386
Hematologic Malignancies Market Report by Type, Therapy, End User, and Region 2024-2032
The global hematologic malignancies market size reached US$ 60.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 122.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032. Growing prevalence of blood cancer, increasing adoption of targeted therapies and immunotherapies tailored to genetic profiles, and expansion of biopharmaceutical pipelines focusing on novel treatments for hematologic cancers are some of the key factors driving the growth of the market.
Hematologic Malignancies Market Analysis:
Major Market Drivers: The rising incidence of hematologic malignancies, coupled with an aging population, is driving demand for hematologic malignancy drugs. Additionally, the growing awareness about early diagnosis, along with improving diagnostic modalities, is also contributing to market growth.
Key Market Trends: Innovations in targeted therapies, immunotherapy, and personalized medicine, which are transforming treatment options, improving outcomes, and reducing side effects for patients with hematologic cancers, refer to one of the significant factors catalyzing the hematologic malignancies market revenue.
Competitive Landscape: Some of the leading companies operating in the global market include AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited, among many others.
Geographical Trends: The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.
Challenges and Opportunities: The hematologic malignancies market faces challenges such as high treatment costs, complex disease biology, and the need for personalized therapies. However, opportunities exist in advancing targeted therapies, immunotherapies, and diagnostic technologies to improve patient outcomes and meet the growing demand for effective and personalized cancer care solutions.
Hematologic Malignancies Market Trends:
Rising Prevalence of Blood Cancer
Escalating incidences of blood cancer and a growing emphasis on the development of new treatments are primarily driving the growth in the hematologic malignancies market. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America. Thus, the high incidence of leukemia worldwide is expected to drive the hematologic malignancies market growth. Similarly, according to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. According to the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, a prominent rise in blood cancer cases in the market is expected to propel the hematologic malignancies market value over the forecasted period.
Growing Number of Product Launches, Partnerships, and Collaborations
Numerous companies are implementing diverse strategic initiatives such as launching new products, forming partnerships, fostering collaborations, and engaging in mergers and acquisitions to enhance their market presence. This, in turn, is positively impacting the hematologic malignancies market outlook. For instance, in October 2020, AstraZeneca Pharma India announced the launch of Acalabrutinib 100 mg capsules, which are used for the treatment of various types of leukemias (leukemia (CLL) and small lymphocytic lymphoma) under the brand name Calquence. Similarly, in January 2024, Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets. Such innovations are projected to augment the hematologic malignancies market demand in the coming years.
Increasing Product Approvals
Various concerned regulatory authorities are increasingly approving hematologic malignancies drugs, which is creating a positive outlook for the overall market. For instance, in September 2020, the US FDA approved Bristol Myers Squibb's azacytidine (Onureg) 300 mg tablets, CC-486, to continue treating adult patients with acute myeloid leukemia. Similarly, in March 2021, Sanofi SA received US FDA approval for its Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. In line with this, in February 2021, TG Therapeutics Inc. received the US FDA accelerated approval for its UKONIQ (umbralisib), an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL). Significant growth in number of approved drugs for treating blood cancer is propelling the hematologic malignancies market value.
Global Hematologic Malignancies Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global hematologic malignancies market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, therapy, and end user.
Breakup by Type:
Leukemia
Lymphoma
Multiple Myeloma
Others
The hematologic malignancies market report has provided a detailed breakup and analysis of the market based on the type. This includes leukemia, lymphoma, multiple myeloma, and others.
Leukemia is a type of hematologic malignancy, also known as blood cancer, that originates in the bone marrow and affects the production of blood cells. The rising cases of leukemia across the globe are bolstering the hematologic malignancies market share. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America.
Furthermore, the significant rise in the multiple myeloma market is a clear indication of the need for increased research and development. For instance, according to the Global Cancer Observatory, in 2020, nearly 35,318 cases of multiple myeloma were reported in the North American region. This rise in multiple myeloma cases underscores the importance of your work and is positively influencing the hematologic malignancies market price trends.
Breakup by Therapy:
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
The report has provided a detailed breakup and analysis of the market based on the therapy. This includes chemotherapy, radiotherapy, immunotherapy, stem cell transplantation, and others.
As per the hematologic malignancies market overview by IMARC, for most types of blood cancers, chemotherapy is the common treatment. The large patient pool and the increasing incidence of blood cancers are the major drivers augmenting the need for chemotherapy. For instance, in June 2019, the United States Food and Drug Administration granted approval to Polivy to be used in combination with the chemotherapy drug bendamustine and rituximab to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.
Breakup by End User:
Hospitals
Diagnostics Centers
Research Centers
Others
The hematologic malignancies market research report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostics centers, research centers, and others.
Hospitals are primary end users in the hematologic malignancies market, providing diagnosis, treatment, and ongoing care for patients with blood cancers, such as leukemia, lymphoma, and myeloma. They offer a range of specialized services, including chemotherapy, radiation therapy, stem cell transplantation, and supportive care. Hospitals also serve as centers for clinical trials and research, driving advancements in treatment options and patient outcomes.
Diagnostics centers are essential for early detection and monitoring of hematologic malignancies through a variety of tests, including blood tests, bone marrow biopsy, imaging studies, and genetic testing. These centers provide accurate diagnostic services, enabling healthcare providers to initiate timely treatment strategies. Diagnostics centers often collaborate closely with hospitals and oncology clinics to ensure comprehensive patient care and management throughout the treatment journey.
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.
Besides this, hematologic malignancies market statistics indicates that the presence of key players, the high prevalence of blood cancer patients, established healthcare infrastructure, and the availability of branded drugs in North America and Asia Pacific countries are positively impacting the hematologic malignancies industry. According to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. As per the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, the increasing number of blood cancer cases in the region is a major driving factor for the growth of the market. Besides this, hematologic malignancies market forecast by IMARC indicates that beneficial government initiatives and an increase in the number of research partnerships are further contributing to the market growth. For instance, in December 2020, the Leukemia and Lymphoma Society (LLS) initiated a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly US$ 17 Million in research grants to progress the research in finding effective treatment options for patients with leukemia, lymphoma, myeloma, and other blood cancers.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the detailed profiles of the following key players:
AbbVie Inc.
AstraZeneca plc
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co. Inc
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Global Hematologic Malignancies Market News:
June 2024: The University of Cincinnati Cancer Center launched a new treatment center dedicated specifically to blood cancers. It is the university's first state-of-the-art center devoted to blood cancer care in the United States.
June 2024: Fortis inaugurated a state-of-the-art facility for the specialized treatment of blood cancers and disorders.
January 2024: Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets.
Key Questions Answered in This Report:
- How big is the hematologic malignancies market?
- How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global hematologic malignancies market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the therapy?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global hematologic malignancies market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Hematologic Malignancies Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Leukemia
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Lymphoma
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Multiple Myeloma
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Therapy
- 7.1 Chemotherapy
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Radiotherapy
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Immunotherapy
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Stem Cell Transplantation
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Diagnostics Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Research Centers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AbbVie Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 AstraZeneca plc
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bristol-Myers Squibb Company
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Eli Lilly and Company
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 F. Hoffmann-La Roche Ltd
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.6 GlaxoSmithKline plc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Johnson & Johnson
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Merck & Co. Inc
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Novartis AG
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Pfizer Inc.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Sanofi S.A.
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Takeda Pharmaceutical Company Limited
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis
- 14.3.1 AbbVie Inc.
List of Figures
- Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges
- Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2023
- Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2023
- Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2023
- Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2023
- Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
- Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2023
- Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
- Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
- Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2023 and 2032
- Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million US$), 2024-2032
- Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
- Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million US$), 2024-2032
- Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 6: Global: Hematologic Malignancies Market: Competitive Structure
- Table 7: Global: Hematologic Malignancies Market: Key Players
